- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
For: Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionPoland · Hungary · Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
For: Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionGermany · Poland · Austria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)
This study is testing a new medicine, bemarituzumab, for people with certain solid tumours that have a specific marker called FGFR2b overdue. It will look at how safe the medicine is and if it can shrink or stop the growth of these cancers.
For: Solid tumoursFrance · Hungary · Romania - Active not recruitingPHASE3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
This study looks at a new drug, bemarituzumab, in combination with standard chemotherapy and nivolumab for advanced stomach or food pipe cancer. It aims to see if this new combination is safe and works better than current treatments, helping people with specific types of cancer live longer.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)
This study looks at a new combination of a drug called bemarituzumab with standard chemotherapy for stomach and food pipe cancer. It checks how well this new treatment shrinks tumours before surgery in people with a specific type of cancer.
For: gastric and gastro-oesophageal junction adenocarcinomasFrance